Nektar Therapeutics (NKTR) Tops Q3 EPS by 18c
Tweet
Share
E-mailGet Alerts NKTR Hot Sheet
Price: $63.65 +2.61%
Revenue Growth %: -7.1%
Financial Fact:
Other income (expense), net: 332K
Today's EPS Names:
CGEH, NAKA, APOG, More
Revenue Growth %: -7.1%
Financial Fact:
Other income (expense), net: 332K
Today's EPS Names:
CGEH, NAKA, APOG, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q3 EPS of ($0.06), $0.18 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $60 million versus the consensus estimate of $44.3 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
- Darden Restaurants (DRI) PT Raised to $240 at UBS as Stock Remains a 'Quality Compounder'
- Argus starts SpaceX at Hold, sees record IPO as a multi-year re-rating challenge
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
